Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
GE’s blood speckle imaging (BSI) software shows the flow of blood cells’ trajectories. It is a form of blood vector flow imaging.

GE’s blood speckle imaging (BSI) software offers the ability to view a graphical representation of the blood cells’ trajectories.

News | Cardiovascular Ultrasound| September 01, 2017
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advance
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init